Abel A. Ricárdez-Espinosa, Departamento de Urología, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional Adolfo Ruiz Cortines, Instituto Mexicano del Seguro Social, Veracruz, México
Erick Rojas-Hernández, Departamento de Urología, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional Adolfo Ruiz Cortines, Instituto Mexicano del Seguro Social (IMSS), Veracruz, Veracruz, México
Jose M. Reyes-Ruiz, Departamento de Educación e Investigación. Unidad Médica de Alta especialidad No. 14 Adolfo Ruiz Cortines, Veracruz, Veracruz, México
Javier F. Salazar-Angulo, Departamento de Urología, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional Adolfo Ruiz Cortines, Instituto Mexicano del Seguro Social (IMSS), Veracruz, Veracruz, México
Luis A. Jiménez-López, Dirección de Educación e Investigación en Salud, Unidad Médica de Alta Especialidad, Hospital de Especialidades No. 14, Centro Médico Nacional Adolfo Ruiz Cortines, Instituto Mexicano del Seguro Social, Veracruz, México
Objective: To evaluate the usefulness of the preoperative systemic immune-inflammatory index (SII) as predictor of locally advanced or metastatic renal cell carcinoma (RCC). Method: Retrospective, single-center, observational and analytical study performed in a tertiary hospital in Mexico. Patients diagnosed with CRC during January 2021 to July 2022 were included and stratified into localized CRC (clinical stage I and II) and locally advanced or metastatic CRC (clinical stage III and IV). Spearman correlation analysis, receiver operating characteristic (ROC) curve and Youden index were performed. Results: A total of 85 patients with clinical stage I-II (n = 35) and III-IV (n = 50) CRC were included in the study. Forty-seven patients (56%) were male and thirty-eight (44%) were female. The median age for stage I-II patients was 59.06 (12.433) years and for stage III-IV patients was 61.83 (10.001) years (p = 0.416). IIS correlated with tumor size (r = 0.376; p = 0.001) and had an area under the curve of 0.77 (95% confidence interval: 0.66-0.85; p < 0.0001). The optimal cutoff point for IIS was > 637.2829, with a sensitivity of 74% and a specificity of 71.43%. Conclusions: This study demonstrated the correlation between IIS and tumor size. Preoperative IIS could be an indicator of clinical stage III-IV CRC. IIS is an effective and simple clinical tool in the preoperative evaluation of patients diagnosed with CRC.
Keywords: Renal cell carcinoma. Systemic immune-inflammatory index. Preoperative prognostic value.